The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

is an mRNA-based vaccine that sends signals to your cells to produce the same protein F that causes the immune reaction that fights against RSV. These vaccines are recommended and available for ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

RSV Vaccines Effective ... VISION Network researchers report that across the board these ... New mRNA Vaccine Created to Prevent and Treat C. Difficile Oct. 17, 2024 — A new vaccine provides ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024 ... This figure includes a mere $10 million in sales of the new RSV vaccine following its third-quarter launch, underscoring the ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...